Do analysts rate THAR or PLUR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is THAR or PLUR more profitable?

Tharimmune has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat Tharimmune's return on equity. Company Net Margins Return on Equity Return on Assets Tharimmune N/A -588.45% -264.41% Pluri -2,162.08% N/A -106.59%

Do analysts prefer LFVN or PLUR?

Lifevantage presently has a consensus price target of $5.00, suggesting a potential downside of 23.43%. Given Lifevantage's stronger consensus rating and higher possible upside, equities research analysts plainly believe Lifevantage is more favorable than Pluri. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lifevantage 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, LFVN or PLUR?

Lifevantage has higher revenue and earnings than Pluri. Pluri is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lifevantage $228.53M 0.36 $9.81M $0.45 14.51 Pluri $1.34M 14.33 -$22.58M -$4.53 N/A

Is LFVN or PLUR more profitable?

Lifevantage has a net margin of 2.94% compared to Pluri's net margin of -2,162.08%. Lifevantage's return on equity of 23.89% beat Pluri's return on equity. Company Net Margins Return on Equity Return on Assets Lifevantage 2.94% 23.89% 12.47% Pluri -2,162.08% N/A -106.59%

Do analysts recommend PLUR or FRMM?

Forum Markets has a consensus target price of $10.00, suggesting a potential upside of 74.52%. Given Forum Markets' stronger consensus rating and higher probable upside, analysts plainly believe Forum Markets is more favorable than Pluri. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Forum Markets 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has better valuation and earnings, PLUR or FRMM?

Pluri has higher earnings, but lower revenue than Forum Markets. Pluri is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pluri $1.34M 14.33 -$22.58M -$4.53 N/A Forum Markets $6.55M 11.71 -$450.52M -$36.07 N/A

Is PLUR or FRMM more profitable?

Forum Markets has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat Forum Markets' return on equity. Company Net Margins Return on Equity Return on Assets Pluri -2,162.08% N/A -106.59% Forum Markets N/A -242.09% -135.46%

Do analysts recommend PLUR or ENLV?

Enlivex Therapeutics has a consensus price target of $247.50, suggesting a potential upside of 5,792.86%. Given Enlivex Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Enlivex Therapeutics is more favorable than Pluri. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Enlivex Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Do analysts recommend TELO or PLUR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Pluri (PLUR) Competitors

$1.78 -0.02 (-0.84%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$1.78 +0.00 (+0.28%)

As of 07/24/2026 07:21 PM Eastern

Compare

PLUR vs. THAR, LFVN, FRMM, ENLV, and TELO

Should you buy Pluri stock or one of its competitors? MarketBeat compares Pluri with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pluri include Tharimmune (THAR), Lifevantage (LFVN), Forum Markets (FRMM), Enlivex Therapeutics (ENLV), and Telomir Pharmaceuticals (TELO). These companies are all part of the "pharmaceutical products" industry.

How does Pluri compare to Tharimmune?

Tharimmune (NASDAQ:THAR) and Pluri (NASDAQ:PLUR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

In the previous week, Tharimmune and Tharimmune both had 1 articles in the media. Tharimmune's average media sentiment score of 1.25 beat Pluri's score of 0.94 indicating that Tharimmune is being referred to more favorably in the media.

Company	Overall Sentiment
Tharimmune	Positive
Pluri	Positive

Tharimmune has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market. Comparatively, Pluri has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market.

1.2% of Tharimmune shares are owned by institutional investors. Comparatively, 16.6% of Pluri shares are owned by institutional investors. 6.7% of Tharimmune shares are owned by insiders. Comparatively, 43.2% of Pluri shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Tharimmune has higher earnings, but lower revenue than Pluri. Tharimmune is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A
Pluri	$1.34M	14.33	-$22.58M	-$4.53	N/A

Tharimmune has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tharimmune	N/A	-588.45%	-264.41%
Pluri	-2,162.08%	N/A	-106.59%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Pluri beats Tharimmune on 6 of the 11 factors compared between the two stocks.

How does Pluri compare to Lifevantage?

Lifevantage (NASDAQ:LFVN) and Pluri (NASDAQ:PLUR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

Lifevantage presently has a consensus price target of $5.00, suggesting a potential downside of 23.43%. Given Lifevantage's stronger consensus rating and higher possible upside, equities research analysts plainly believe Lifevantage is more favorable than Pluri.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifevantage	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lifevantage has higher revenue and earnings than Pluri. Pluri is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifevantage	$228.53M	0.36	$9.81M	$0.45	14.51
Pluri	$1.34M	14.33	-$22.58M	-$4.53	N/A

35.3% of Lifevantage shares are owned by institutional investors. Comparatively, 16.6% of Pluri shares are owned by institutional investors. 22.0% of Lifevantage shares are owned by company insiders. Comparatively, 43.2% of Pluri shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Lifevantage has a net margin of 2.94% compared to Pluri's net margin of -2,162.08%. Lifevantage's return on equity of 23.89% beat Pluri's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifevantage	2.94%	23.89%	12.47%
Pluri	-2,162.08%	N/A	-106.59%

Lifevantage has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market. Comparatively, Pluri has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market.

In the previous week, Lifevantage and Lifevantage both had 1 articles in the media. Lifevantage's average media sentiment score of 1.47 beat Pluri's score of 0.94 indicating that Lifevantage is being referred to more favorably in the media.

Company	Overall Sentiment
Lifevantage	Positive
Pluri	Positive

Summary

Lifevantage beats Pluri on 12 of the 14 factors compared between the two stocks.

How does Pluri compare to Forum Markets?

Pluri (NASDAQ:PLUR) and Forum Markets (NASDAQ:FRMM) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

16.6% of Pluri shares are held by institutional investors. Comparatively, 4.1% of Forum Markets shares are held by institutional investors. 43.2% of Pluri shares are held by company insiders. Comparatively, 25.2% of Forum Markets shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Forum Markets has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat Forum Markets' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pluri	-2,162.08%	N/A	-106.59%
Forum Markets	N/A	-242.09%	-135.46%

Forum Markets has a consensus target price of $10.00, suggesting a potential upside of 74.52%. Given Forum Markets' stronger consensus rating and higher probable upside, analysts plainly believe Forum Markets is more favorable than Pluri.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Forum Markets	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Forum Markets had 1 more articles in the media than Pluri. MarketBeat recorded 2 mentions for Forum Markets and 1 mentions for Pluri. Pluri's average media sentiment score of 0.94 equaled Forum Markets'average media sentiment score.

Company	Overall Sentiment
Pluri	Positive
Forum Markets	Positive

Pluri has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market. Comparatively, Forum Markets has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market.

Pluri has higher earnings, but lower revenue than Forum Markets. Pluri is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pluri	$1.34M	14.33	-$22.58M	-$4.53	N/A
Forum Markets	$6.55M	11.71	-$450.52M	-$36.07	N/A

Summary

Forum Markets beats Pluri on 8 of the 15 factors compared between the two stocks.

How does Pluri compare to Enlivex Therapeutics?

Pluri (NASDAQ:PLUR) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.

Enlivex Therapeutics has lower revenue, but higher earnings than Pluri. Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pluri	$1.34M	14.33	-$22.58M	-$4.53	N/A
Enlivex Therapeutics	N/A	N/A	$1.24B	-$8.25	N/A

In the previous week, Enlivex Therapeutics had 7 more articles in the media than Pluri. MarketBeat recorded 8 mentions for Enlivex Therapeutics and 1 mentions for Pluri. Pluri's average media sentiment score of 0.94 beat Enlivex Therapeutics' score of 0.92 indicating that Pluri is being referred to more favorably in the media.

Company	Overall Sentiment
Pluri	Positive
Enlivex Therapeutics	Positive

16.6% of Pluri shares are held by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are held by institutional investors. 43.2% of Pluri shares are held by insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Enlivex Therapeutics has a consensus price target of $247.50, suggesting a potential upside of 5,792.86%. Given Enlivex Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Enlivex Therapeutics is more favorable than Pluri.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Pluri has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market. Comparatively, Enlivex Therapeutics has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market.

Enlivex Therapeutics has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Enlivex Therapeutics' return on equity of 248.08% beat Pluri's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pluri	-2,162.08%	N/A	-106.59%
Enlivex Therapeutics	N/A	248.08%	206.39%

Summary

Enlivex Therapeutics beats Pluri on 10 of the 15 factors compared between the two stocks.

How does Pluri compare to Telomir Pharmaceuticals?

Telomir Pharmaceuticals (NASDAQ:TELO) and Pluri (NASDAQ:PLUR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

Telomir Pharmaceuticals has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%
Pluri	-2,162.08%	N/A	-106.59%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Telomir Pharmaceuticals had 2 more articles in the media than Pluri. MarketBeat recorded 3 mentions for Telomir Pharmaceuticals and 1 mentions for Pluri. Telomir Pharmaceuticals' average media sentiment score of 1.08 beat Pluri's score of 0.94 indicating that Telomir Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Telomir Pharmaceuticals	Positive
Pluri	Positive

Telomir Pharmaceuticals has higher earnings, but lower revenue than Pluri. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A
Pluri	$1.34M	14.33	-$22.58M	-$4.53	N/A

Telomir Pharmaceuticals has a beta of -0.25, meaning that its share price is 125% less volatile than the broader market. Comparatively, Pluri has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market.

16.6% of Pluri shares are owned by institutional investors. 43.2% of Pluri shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Telomir Pharmaceuticals beats Pluri on 7 of the 13 factors compared between the two stocks.

Get Pluri News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLUR vs. The Competition

Export

Metric	Pluri	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$19.21M	$3.67B	$6.86B	$12.25B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-0.39	21.48	27.14	23.64
Price / Sales	14.33	169.92	517.01	89.03
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	-16.18	7.88	10.28	6.07
Net Income	-$22.58M	$23.86M	$3.60B	$331.99M
7 Day Performance	-4.30%	-3.82%	-1.27%	-0.63%
1 Month Performance	-17.59%	-2.61%	-0.37%	-2.00%
1 Year Performance	-65.50%	32.79%	18.30%	13.62%

Pluri Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLUR Pluri	0.4007 of 5 stars	$1.78 -0.8%	N/A	-65.2%	$19.21M	$1.34M	N/A	150	Analyst Downgrade
THAR Tharimmune	0.0757 of 5 stars	$2.16 +5.4%	N/A	+34.6%	$81.50M	N/A	N/A	2	Gap Up
LFVN Lifevantage	2.7366 of 5 stars	$6.32 -1.3%	$5.00 -20.9%	-53.3%	$79.76M	$228.53M	14.04	260	Positive News
FRMM Forum Markets	3.8568 of 5 stars	$5.90 -3.8%	$10.00 +69.6%	N/A	$78.95M	$6.55M	N/A	7	Analyst Upgrade
ENLV Enlivex Therapeutics	3.1993 of 5 stars	$4.64 -1.9%	$247.50 +5,234.1%	-75.5%	$78.10M	N/A	N/A	70	News Coverage Analyst Upgrade Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLUR) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pluri (PLUR) Competitors